Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,

#4642 Establishing a standardised histopathological grading system for mesenteric fibrosis in small intestinal neuroendocrine tumours

Introduction: Mesenteric fibrosis (MF) frequently develops around mesenteric metastasis in small intestinal neuroendocrine tumour (SI-NET) patients. Since MF is not always detected radiologically, histopathological examination is considered the gold standard. However, there is no uniform histopathological scoring system for MF correlated with clinical data.

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, Hofland L, Hall A, Iyer A,

Keywords: small intestinal neuroendocrine tumour, mesenteric fibrosis, grading system,

#4632 MEN1 associated pancreatic neuroendocrine tumours: Re-evaluating the 2cm cut-off for surgical resection

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the leading cause of death in patients (pts) with MEN1. Screening is recommended to diagnose early and prevent metastases. The optimal cut-off of when to intervene in a PanNET is still an area of debate.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: MEN1, Pan NET,